Although most of the research on alpha-1 antagonists for PTSD and substance use disorders has been done with prazosin, there is increasing interest in doxazosin due to its significantly longer half-life, which theoretically would increase tolerability. Here, PSMA6 is linked to post-traumatic stress disorder.